Table 1.
(Neo)adjuvant chemotherapy
| (Neo)adjuvant treatment | Population | Phase | Total n (SS) | Outcome | Year of publication |
|---|---|---|---|---|---|
| Histology-tailored neoadjuvant chemotherapy in 5 types of STS. For SS: high-dose ifosfamide (14 g/m2 in 14 days) every 28 days vs. epirubicine + ifosfamide 9 g/m2 in 3 days every 21 days [15••] | SS LMS mLPS MPNST UPS |
III | 287 (70) | DFS after 46 months histology-tailored chemotherapy 38% vs. standard group 46%, OS 89% vs. 64% (both significant, median follow-up 12.3 months, 70 events) Subgroup analysis: standard chemotherapy favorable for SS (HR 1.85, 95% CI 0.65–5.22, 17/70 events) |
2017 |
| Doxorubicin 75 mg/m2, ifosfamide 5 g/m2, and lenograstim q 3 weeks for 5 cycles adjuvant vs. active controle. 73% also had radiotherapy [16] | STS | III | 351 (40) | Median OS 12.4 vs. 11.2 years (not significant) 5 years EFS: 52.9 vs. 54.9% 5 years OS 67.8 vs. 66.5% |
2012 |
| Doxorubicin 60 mg/m2 and ifosfamide 10 g/m2 for 3 neoadjuvant and 2 adjuvant courses [17] | STS | II | 70 (20) | 2 years PFS 75.7% 5 years PFS 63.8% 5 years OS 82.6% |
2015 |
| Doxorubicin 37.5 mg/m2 for 2 days and ifosfamide 3 g/m2 for 3 days followed by 2 cycles of ifosfamide 3 g/m2 for 2 days [18] | SS | II | 138 | 3 years EFS 81.9% 5 years EFS 80.7% 3 years OS 97.2% 5 years OS 90.7% |
2015 |
| Not specified [19] | SS stage I–III | IV | 544 pts. of whom 131 received chemotherapy | Hazard ratio chemotherapy for OS: - overall cohort: 0.95 (0.63–1.44) - stage I 4.80 (0.91–25.3) - stage IIA 1.32 (0.54–3.20) - stage IIB 0.36 (0.07–1.76) - stage III 0.56 (0.33–0.93), p = 0.028 |
2017 |
SS synovial sarcoma, STS soft tissue sarcoma, MLPS myxoid liposarcoma, MPNST malignant peripheral nerve sheath tumor, UPS undifferentiated pleiomorphic sarcoma, DFS disease free survival, OS overall survival, PFS progression free survival, EFS event free survival